INBIOGEN (101140) Fundamentals 2026 — Revenue Analysis | SniperIQ
INBIOGEN (101140) is a KR-listed Consumer Cyclical company in Apparel - Footwear & Accessories with a market capitalization of ₩49.8B, trading at ₩4985.00 on the KSC. This SniperIQ fundamentals page covers INBIOGEN's valuation, profitability (net margin -333.0%), revenue (₩6.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is INBIOGEN's market cap?
INBIOGEN (101140) has a market capitalization of approximately ₩49.8B, trading at ₩4985.00 on the KSC. Market cap moves with the live share price.
What is INBIOGEN's P/E ratio?
INBIOGEN's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.3x. Valuation multiples are best compared with Consumer Cyclical sector peers rather than read in isolation.
How profitable is INBIOGEN?
INBIOGEN runs a net profit margin of -333.0%, a gross margin of -8.9%, and an operating margin of -73.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does INBIOGEN generate?
INBIOGEN reported revenue of ₩6.3B for fiscal year 2025, with net income of ₩5.8B and earnings per share (EPS) of 579.79. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does INBIOGEN pay a dividend?
INBIOGEN does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is INBIOGEN financially healthy?
INBIOGEN carries a debt-to-equity ratio of 0.03x and a current ratio of 1.57x, with a market beta of 0.66. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is INBIOGEN a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For INBIOGEN (101140) the key facts are: market cap ₩49.8B, revenue ₩6.3B, 52-week range 4890-14300. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Cyclical peers and form your own view.
Track INBIOGEN's full fundamentals live
Get INBIOGEN's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.